Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry

M. Gwechenberger, G. Barón-Esquivias, TAC. de Vries, JM. Siller-Matula, MC. Manu, JAG. Souza, S. Wienerroither, L. Pecen, JR. de Groot, R. De Caterina, P. Kirchhof, ETNA-AF-Europe Investigators

. 2024 ; 3 (4) : 100880. [pub] 20240311

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013075

BACKGROUND: Managing patients with atrial fibrillation (AF) and worsening renal function (WRF) remains a clinical challenge due to the need of dose adjustment of non-vitamin K antagonist oral anticoagulants. OBJECTIVES: To determine the incidence of WRF in patients with AF treated with edoxaban, the association of WRF with clinical outcomes, and predictors of WRF and clinical outcomes in these patients. METHODS: This is a subanalysis of the Edoxaban Treatment in routiNe clinical prActice for patients with non-valvular Atrial Fibrillation in Europe study (NCT02944019), an observational study of edoxaban-treated patients with AF. WRF was defined as a ≥25% reduction in creatinine clearance between baseline and 2 years. RESULTS: Of the 9,054 patients included (69% of the total 13,133 enrolled), most did not experience WRF (90.3%) during the first 2 years of follow-up. WRF occurred in 9.7% of patients. Patients with WRF had significantly higher rates of all-cause death (3.88%/y vs 1.88%/y; P < 0.0001), cardiovascular death (2.09%/y vs 0.92%/y; P < 0.0001), and major bleeding (1.51%/y vs 0.98%/y; P = 0.0463) compared with those without WRF. Rates of intracranial hemorrhage (0.18%/y vs 0.18%/y) and of any stroke/systemic embolic events were low (0.90%/y vs 0.69%/y; P = 0.3161) in both subgroups. The strongest predictors of WRF were a high CHA2DS2-VASc score, high baseline creatinine clearance, low body weight, and older age. Most predictors of WRF were also predictors of clinical outcomes. CONCLUSIONS: WRF occurred in approximately 10% of edoxaban-treated AF patients. Rates of death and major bleeding were significantly higher in patients with WRF than without. Stroke events were low in both subgroups.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013075
003      
CZ-PrNML
005      
20240726151518.0
007      
ta
008      
240723s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacadv.2024.100880 $2 doi
035    __
$a (PubMed)38939675
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gwechenberger, Marianne $u Department of Cardiology, Medical University of Vienna, Vienna, Austria
245    10
$a Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry / $c M. Gwechenberger, G. Barón-Esquivias, TAC. de Vries, JM. Siller-Matula, MC. Manu, JAG. Souza, S. Wienerroither, L. Pecen, JR. de Groot, R. De Caterina, P. Kirchhof, ETNA-AF-Europe Investigators
520    9_
$a BACKGROUND: Managing patients with atrial fibrillation (AF) and worsening renal function (WRF) remains a clinical challenge due to the need of dose adjustment of non-vitamin K antagonist oral anticoagulants. OBJECTIVES: To determine the incidence of WRF in patients with AF treated with edoxaban, the association of WRF with clinical outcomes, and predictors of WRF and clinical outcomes in these patients. METHODS: This is a subanalysis of the Edoxaban Treatment in routiNe clinical prActice for patients with non-valvular Atrial Fibrillation in Europe study (NCT02944019), an observational study of edoxaban-treated patients with AF. WRF was defined as a ≥25% reduction in creatinine clearance between baseline and 2 years. RESULTS: Of the 9,054 patients included (69% of the total 13,133 enrolled), most did not experience WRF (90.3%) during the first 2 years of follow-up. WRF occurred in 9.7% of patients. Patients with WRF had significantly higher rates of all-cause death (3.88%/y vs 1.88%/y; P < 0.0001), cardiovascular death (2.09%/y vs 0.92%/y; P < 0.0001), and major bleeding (1.51%/y vs 0.98%/y; P = 0.0463) compared with those without WRF. Rates of intracranial hemorrhage (0.18%/y vs 0.18%/y) and of any stroke/systemic embolic events were low (0.90%/y vs 0.69%/y; P = 0.3161) in both subgroups. The strongest predictors of WRF were a high CHA2DS2-VASc score, high baseline creatinine clearance, low body weight, and older age. Most predictors of WRF were also predictors of clinical outcomes. CONCLUSIONS: WRF occurred in approximately 10% of edoxaban-treated AF patients. Rates of death and major bleeding were significantly higher in patients with WRF than without. Stroke events were low in both subgroups.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Barón-Esquivias, Gonzalo $u Virgen del Rocio University Hospital, University of Seville, Seville, Spain
700    1_
$a de Vries, Tim A C $u Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands $u Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam, the Netherlands $u Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands
700    1_
$a Siller-Matula, Jolanta M $u Department of Cardiology, Medical University of Vienna, Vienna, Austria
700    1_
$a Manu, Marius C $u Daiichi Sankyo Europe GmbH, Munich, Germany
700    1_
$a Souza, José A G $u Daiichi Sankyo Europe GmbH, Munich, Germany
700    1_
$a Wienerroither, Sebastian $u Daiichi Sankyo Austria GmbH, Vienna, Austria
700    1_
$a Pecen, Ladislav $u Institute of Computer Science of the Czech Academy of Sciences, Prague, Czech Republic $u Department of Immunochemistry Diagnostics, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a de Groot, Joris R $u Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands $u Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam, the Netherlands
700    1_
$a De Caterina, Raffaele $u Cardiology Division, University of Pisa, Pisa, Italy $u Fondazione VillaSerena per la Ricerca, Pescara, Italy
700    1_
$a Kirchhof, Paulus $u Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK $u University Heart and Vascular Centre Hamburg, University Medical Centre Hamburg Eppendorf, Hamburg, Germany $u German Center for Cardiovascular Sciences (DZHK) Partner Site Hamburg/Kiel/Lübeck, Hamburg/Kiel/Lübeck, Germany
710    2_
$a ETNA-AF-Europe Investigators
773    0_
$w MED00215007 $t JACC: Advances $x 2772-963X $g Roč. 3, č. 4 (2024), s. 100880
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38939675 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151510 $b ABA008
999    __
$a ok $b bmc $g 2125591 $s 1224938
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 3 $c 4 $d 100880 $e 20240311 $i 2772-963X $m JACC: Advances $n JACC Adv $x MED00215007
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace